You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
The Authors' reply
  1. Nicoline J Breet1,2,
  2. Jochem W van Werkum1,2,
  3. Heleen J Bouman1,2,
  4. Johannes C Kelder1,2,
  5. Ankie M Harmsze3,
  6. Christian M Hackeng2,4,
  7. Jurriën M ten Berg1,2
  1. 1Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands
  2. 2St Antonius Center for Platelet Function research, Nieuwegein, The Netherlands
  3. 3Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
  4. 4Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, The Netherlands
  1. Correspondence to Dr Jurriën M ten Berg, Department of Cardiology, St. Antonius Hospital, P.O. Box 2500, Nieuwegein 3435 CM, The Netherlands; j.ten.berg{at}antoniusziekenhuis.nl

https://doi.org/10.1136/heartjnl-2011-301435

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors' reply We thank Dr Jeong and colleagues for their comments1 regarding the incidence of dual high on-treatment platelet reactivity in patients undergoing elective percutaneous coronary intervention and its impact on clinical outcome.2 They raise several important issues.

    First, they provide additional information on the optimal cut-off value of the VerifyNow platelet function test to detect high on-aspirin platelet reactivity. Due to a lack of consensus on the optimal method to quantify high on-aspirin platelet reactivity and on the cut-off value associated with clinical risk, the measurement of platelet reactivity has not been widely implemented and included in the guidelines. Furthermore, the correlation between platelet function tests is moderate and …

    View Full Text

    Footnotes

    • Linked article 301129.

    • Funding Siemens Healthcare Diagnostics provided the Dade PFA Collagen/ADP Test Cartridge and the novel INNOVANCE PFA P2Y* free-of-charge in the POPular study. Siemens Healthcare Diagnostics was not involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; or in the preparation, review and approval of the manuscript.

    • Competing interests JWvW received speaker's fee from Accumetrics and Siemens, Consultancy, The Medicines Company; JMtB received speaker's fee from Sanofi-Aventis, Eli Lilly, BMS and MSD, Consultancy Sanofi-Aventis, Schering-Plough and Glaxo Smith Kline.

    • Ethics approval This study was conducted with the approval of the Verenigde Commissie Mensgebonden Onderzoek.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles